Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Advance's Summer College Institute to take place from August 5-12

Advance LA announced today its newest program, The Summer College Institute. This innovative program will take place August 5-12, 2012, on the campus of American Jewish University in Los Angeles.

11 Jun 2012

With Adderall shortage, drug counterfeiters try to seize a market opportunity

A shortage of Adderall began last year, sending millions of people with attention deficit/hyperactivity disorder and narcolepsy on perpetual wild goose chases to find drugstores with the pills they need to stay alert and focused. So it's not surprising that Adderall counterfeiters have seized a big marketing opportunity. What is surprising is their clumsiness.

31 May 2012

AssureRx closes $12.5M Series C financing

AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.

31 May 2012

Zebrafish can modify their behaviour in response to varying situations

Scientists at Queen Mary, University of London have shown that zebrafish could be used to study the underlying causes of psychiatric disorders.

18 May 2012

Nine fine-grained patterns of Internet usage may indicate depression

In a new study analyzing Internet usage among college students, researchers at Missouri University of Science and Technology have found that students who show signs of depression tend to use the Internet differently than those who show no symptoms of depression.

17 May 2012

Researchers develop new form of specially bred mouse that mimics ADHD

The number of attention deficit hyperactivity disorder (ADHD) cases in the United States are exploding. According to a 2011 statement by the Centers for Disease Control and Prevention, nearly one in 10 American children is diagnosed with the disorder.

11 May 2012

Article evaluates benefits and costs of screening programs for prevention of SCD

An article, published in Circulation by Laurel K. Leslie, MD, MPH from the Tufts Clinical and Translational Science Institute (CTSI) and colleagues from Tufts Medical Center and Floating Hospital for Children at Tufts Medical Center, has evaluated the lifesaving benefits and costs of screening programs for the prevention of sudden cardiac death (SCD) in children and adolescents.

10 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Ritalin use in ADHD rises four-fold over a decade

According to latest figures prescriptions for Ritalin for attention deficit hyperactivity disorder (ADHD) have quadrupled in a decade. This has raised concerns that it is being given to children at the expense of alternative treatments and without appreciation of long-term effects.

8 May 2012

AssureRx introduces new pharmacogenomic test for ADHD

AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

7 May 2012

Scientists address mental health and well-being at Association for Psychological Science's annual meeting

Are our existing treatments for mental health issues working? Can we design new and better approaches to intervention? Can we even tell which factors promote mental health? Clinical psychological scientists will be addressing these and many other questions related to mental health and well-being at the Association for Psychological Science's 24th annual meeting in Chicago, May 24-27, 2012.

3 May 2012

Dopamine linked to willingness to work for a monetary reward

A new brain imaging study has shown that an individual’s willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain. Researchers claim that this could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.

3 May 2012

Autism researcher awarded $1 million grant to apply virtual-reality technology

UC Davis autism researcher and education specialist Peter Mundy has received a $1 million grant from the U.S. Department of Education to apply virtual-reality technology to evaluate social attention and its relation to academic achievement among school children with autism.

3 May 2012

Excessive daytime sleepiness may cause learning, attention and behavior problems

Children who have learning, attention and behavior problems may be suffering from excessive daytime sleepiness, even though clinical tests show them sleeping long enough at night, a new study reports.

2 May 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

2 May 2012

Teenage risky behaviors can be traced to special brain wiring: Study

New research suggests that there is a complex networks of neurons in some youngsters’ brains that make them more likely to begin smoking, experimenting with cannabis or consuming large amounts of alcohol.

30 Apr 2012

Scientists discover number of unknown brain networks linked with teen drug abuse

Why do some teenagers start smoking or experimenting with drugs-while others don't? In the largest imaging study of the human brain ever conducted-involving 1,896 14-year-olds-scientists have discovered a number of previously unknown networks that go a long way toward an answer.

30 Apr 2012

Bullying, ostracism strong predictors of increased symptoms of depression or anxiety

The challenges that come with battling a chronic medical condition or developmental disability are enough to get a young person down. But being left out, ignored or bullied by their peers is the main reason youths with special health care needs report symptoms of anxiety or depression, according to a study to be presented Sunday, April 29, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Advance's Summer College Institute to take place from August 5-12

With Adderall shortage, drug counterfeiters try to seize a market opportunity

AssureRx closes $12.5M Series C financing

Zebrafish can modify their behaviour in response to varying situations

Nine fine-grained patterns of Internet usage may indicate depression

Researchers develop new form of specially bred mouse that mimics ADHD

Article evaluates benefits and costs of screening programs for prevention of SCD

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Ritalin use in ADHD rises four-fold over a decade

AssureRx introduces new pharmacogenomic test for ADHD

Scientists address mental health and well-being at Association for Psychological Science's annual meeting

Dopamine linked to willingness to work for a monetary reward

Autism researcher awarded $1 million grant to apply virtual-reality technology

Excessive daytime sleepiness may cause learning, attention and behavior problems

High-dose glucocorticoids double risk of bacterial infections in children with JIA

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Teenage risky behaviors can be traced to special brain wiring: Study

Scientists discover number of unknown brain networks linked with teen drug abuse

Bullying, ostracism strong predictors of increased symptoms of depression or anxiety

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Industry Focus eBook - Pharmaceutical Manufacturing (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Latest Attention Deficit Hyperactivity Disorder (ADHD) News and Research

Industry Focus eBook - Pharmaceutical Manufacturing (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in